MOUNTAIN VIEW, Calif., Jan. 3 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced that three new companies have signed contracts for the Drug Model Explorer(TM) (DMX(TM)). The new customers include a top-5 major pharmaceutical firm, a fast-growing European pharmaceutical company, and a global pharmaceutical company based in Japan.
“The addition of three new DMX customers in the last quarter is an important milestone for our innovative tool for drug model visualization,” said Shawn O’Connor, Pharsight’s president and chief executive officer. “It is gratifying to see DMX progress from beta testing and first DMX commercial use, to the industry’s recognition of the value of DMX in the Bio IT award, and now to the expansion of the DMX customer base.”
About DMX
DMX allows clinicians, biostatisticians, marketers, and other members of clinical development teams to quickly visualize the modeled efficacy, safety, and other performance attributes of a new drug versus competing therapies. Pharsight believes that DMX will help increase the usage of quantitative-based decision-making in the drug development process. DMX can enhance the entire development team’s understanding of a drug’s likely clinical potential and limitations, and enable more efficient decision-making by providing direct interaction with modeling results presented as a series of intuitive plots and tables.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
Forward Looking Statements
This press release includes forward-looking statements, including statements regarding the anticipated performance of Pharsight’s products and the expected benefits to customers from the use of Pharsight’s products. Actual results may differ materially from Pharsight’s expectations due to a variety of factors, including: general market and business conditions; uncertainties in pharmaceutical drug development; changes in the demand for Pharsight’s products and services; changes in Pharsight’s research and development focus or operating strategies; the failure to develop new products and services or to keep pace with technological changes; delays in the release of new products and services; and the failure of products and services to obtain anticipated levels of customer acceptance or to meet customers’ expectations. Further information on potential factors that could affect actual results is included in Pharsight’s Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 14, 2005. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.
Registered Trademarks and Trademarks
Pharsight(R), Drug Model Explorer(TM) and DMX(TM) are a registered trademarks or are trademarks of Pharsight Corporation.
Pharsight Corporation
CONTACT: investors, Douglas Sherk, +1-415-896-6820, or JenniferBeugelmans, +1-415-896-6820, or media, Steve DiMattia, +1-646-277-8706, allof EVC Group for Pharsight Corporation
Web site: http://www.pharsight.com/
